GlassScriptPhysician profile
Frederick S Sherman
NPI 1255302584
$4,897.50
in general payments reported to CMS, 2019-2025
32 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $249 · 2021: $608 · 2022: $457 · 2023: $740 · 2024: $706 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,587.54 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.54 | 2019-2025 | Linzess, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $569.17 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $446.77 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $418.04 | 2019-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $249.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $197.06 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $151.58 | 2022-2023 | |
| Ardelyx, INC. | $144.69 | 2023-2025 | Ibsrela |
| Pfizer INC. | $140.87 | 2019-2025 | |
| Braintree Laboratories, INC. | $136.58 | 2019-2025 | Suflave, Sutab |
| Celgene Corporation | $133.59 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $106.66 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $103.30 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $80.23 | 2024-2025 | Vegzelma |
| Thd America, INC. | $73.42 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $66.11 | 2025 | Zenpep |
| Allergan, INC. | $65.31 | 2019 | |
| Qol Medical, LLC | $63.27 | 2019-2022 | |
| Redhill Biopharma INC. | $58.14 | 2020-2022 | |
| Intuitive Surgical, INC. | $56.60 | 2019 | |
| Phathom Pharmaceuticals, INC. | $55.97 | 2024 | Voquezna |
| Amgen INC. | $50.50 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $39.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.10 | 2020-2021 | |
| Ucb, INC. | $36.16 | 2019 | |
| Ironwood Pharmaceuticals, INC | $36.10 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.73 | 2023 | Dupixent |
| Vivus LLC | $23.99 | 2025 | Pancreaze |
| Novo Nordisk INC | $23.60 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo |
| Fujifilm Healthcare Americas Corporation | $15.02 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,608.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.